{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:51:28Z","timestamp":1773370288183,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"DOI":"10.1007\/s00125-026-06705-6","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:39:06Z","timestamp":1773329946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0174-4549","authenticated-orcid":false,"given":"Martina","family":"Chiriac\u00f2","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7633-1346","authenticated-orcid":false,"given":"Domenico","family":"Tric\u00f2","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-2005","authenticated-orcid":false,"given":"Alberto","family":"Giannoni","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7005-1215","authenticated-orcid":false,"given":"Luca","family":"Sacchetta","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-6496","authenticated-orcid":false,"given":"Lorenzo","family":"Nesti","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8296-4238","authenticated-orcid":false,"given":"Simona","family":"Baldi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-2295","authenticated-orcid":false,"given":"Tiziana","family":"Scozzaro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-2328","authenticated-orcid":false,"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8465-7717","authenticated-orcid":false,"given":"Andrea","family":"Natali","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-1584","authenticated-orcid":false,"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"23","key":"6705_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568\/SUPPL_FILE\/COTR149_23.PDF","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel SM, Kang YM, Im KA et al (2024) Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. Circulation 149(23):1789\u20131801. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069568","journal-title":"Circulation"},{"key":"6705_CR2","doi-asserted-by":"publisher","first-page":"102272","DOI":"10.1016\/J.COPH.2022.102272","volume":"66","author":"M Chiriac\u00f2","year":"2022","unstructured":"Chiriac\u00f2 M, Tric\u00f2 D, Solini A (2022) Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors. Curr Opin Pharmacol 66:102272. https:\/\/doi.org\/10.1016\/J.COPH.2022.102272","journal-title":"Curr Opin Pharmacol"},{"issue":"15","key":"6705_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMOA2024816\/SUPPL_FILE\/NEJMOA2024816_DATA-SHARING.PDF","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMOA2024816","journal-title":"N Engl J Med"},{"issue":"2","key":"6705_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMOA2204233\/SUPPL_FILE\/NEJMOA2204233_DATA-SHARING.PDF","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMOA2204233","journal-title":"N Engl J Med"},{"issue":"4","key":"6705_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/01.HYP.0000091267.39066.72","volume":"42","author":"E Obarzanek","year":"2003","unstructured":"Obarzanek E, Proschan MA, Vollmer WM et al (2003) Individual blood pressure responses to changes in salt intake: results from the DASH-sodium trial. Hypertension 42(4):459\u2013467. https:\/\/doi.org\/10.1161\/01.HYP.0000091267.39066.72","journal-title":"Hypertension"},{"issue":"7733","key":"6705_CR6","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/BMJ.B4567","volume":"339","author":"P Strazzullo","year":"2009","unstructured":"Strazzullo P, D\u2019Elia L, Kandala NB, Cappuccio FP (2009) Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ 339(7733):1296. https:\/\/doi.org\/10.1136\/BMJ.B4567","journal-title":"BMJ"},{"issue":"5","key":"6705_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1161\/STROKEAHA.111.641043\/SUPPL_FILE\/GARDENER_1200.PDF","volume":"43","author":"H Gardener","year":"2012","unstructured":"Gardener H, Rundek T, Wright CB, Elkind MSV, Sacco RL (2012) Dietary sodium and risk of stroke in the Northern Manhattan Study. Stroke 43(5):1200\u20131205. https:\/\/doi.org\/10.1161\/STROKEAHA.111.641043","journal-title":"Stroke"},{"issue":"2","key":"6705_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/01.HYP.23.2.195","volume":"23","author":"R Bigazzi","year":"1994","unstructured":"Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM (1994) Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 23(2):195\u2013199. https:\/\/doi.org\/10.1161\/01.HYP.23.2.195","journal-title":"Hypertension"},{"issue":"6","key":"6705_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/S11906-019-0948-5","volume":"21","author":"AT Robinson","year":"2019","unstructured":"Robinson AT, Edwards DG, Farquhar WB (2019) The influence of dietary salt beyond blood pressure. Curr Hypertens Rep 21(6):42. https:\/\/doi.org\/10.1007\/S11906-019-0948-5","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"6705_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/NDT\/GFAA120","volume":"36","author":"M Burnier","year":"2021","unstructured":"Burnier M (2021) Sodium intake and progression of chronic kidney disease\u2014has the time finally come to do the impossible: a prospective randomized controlled trial? Nephrol Dial Transplant 36(3):381\u2013384. https:\/\/doi.org\/10.1093\/NDT\/GFAA120","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"6705_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2337\/DC10-1723","volume":"34","author":"EI Ekinci","year":"2011","unstructured":"Ekinci EI, Clarke S, Thomas MC et al (2011) Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care 34(3):703\u2013709. https:\/\/doi.org\/10.2337\/DC10-1723","journal-title":"Diabetes Care"},{"issue":"36","key":"6705_CR12","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/EURHEARTJ\/EHAB368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB368","journal-title":"Eur Heart J"},{"issue":"9","key":"6705_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","volume":"82","author":"SS Virani","year":"2023","unstructured":"Writing Committee Members, Virani SS, Newby LK et al (2023) 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic\u00a0Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 82(9):833\u2013955. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.003","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"6705_CR14","doi-asserted-by":"publisher","first-page":"e003733","DOI":"10.1136\/BMJOPEN-2013-003733","volume":"3","author":"J Powles","year":"2013","unstructured":"Powles J, Fahimi S, Micha R et al (2013) Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 3(12):e003733. https:\/\/doi.org\/10.1136\/BMJOPEN-2013-003733","journal-title":"BMJ Open"},{"issue":"12","key":"6705_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/JAMA.2018.1156","volume":"319","author":"ME Cogswell","year":"2018","unstructured":"Cogswell ME, Loria CM, Terry AL et al (2018) Estimated 24-hour urinary sodium and potassium excretion in US adults. JAMA 319(12):1209\u20131220. https:\/\/doi.org\/10.1001\/JAMA.2018.1156","journal-title":"JAMA"},{"issue":"3","key":"6705_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/J.NUMECD.2020.10.017\/ATTACHMENT\/C514644D-958B-49F8-8C07-B8BC1D9A6F2B\/MMC2.PDF","volume":"31","author":"C Donfrancesco","year":"2021","unstructured":"Donfrancesco C, Lo Noce C, Russo O et al (2021) Trend of salt intake measured by 24-h urine collection in the Italian adult population between the 2008 and 2018 CUORE project surveys. Nutr Metab Cardiovasc Dis 31(3):802\u2013813. https:\/\/doi.org\/10.1016\/J.NUMECD.2020.10.017","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"6705_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jchf.2015.08.007","volume":"4","author":"R Doukky","year":"2016","unstructured":"Doukky R, Avery E, Mangla A et al (2016) Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail 4(1):24\u201335. https:\/\/doi.org\/10.1016\/j.jchf.2015.08.007","journal-title":"JACC Heart Fail"},{"issue":"12","key":"6705_CR18","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/JAMAINTERNMED.2018.4673","volume":"178","author":"KR Mahtani","year":"2018","unstructured":"Mahtani KR, Heneghan C, Onakpoya I et al (2018) Reduced salt intake for heart failure: a systematic review. JAMA Intern Med 178(12):1693\u20131700. https:\/\/doi.org\/10.1001\/JAMAINTERNMED.2018.4673","journal-title":"JAMA Intern Med"},{"issue":"4","key":"6705_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/EJHF.3244","volume":"26","author":"W Mullens","year":"2024","unstructured":"Mullens W, Damman K, Dhont S et al (2024) Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Eur J Heart Fail 26(4):730\u2013741. https:\/\/doi.org\/10.1002\/EJHF.3244","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"6705_CR20","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/EURHEARTJ\/EHX035","volume":"38","author":"W Mullens","year":"2017","unstructured":"Mullens W, Verbrugge FH, Nijst P, Tang WHW (2017) Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J 38(24):1872\u20131882. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHX035","journal-title":"Eur Heart J"},{"issue":"6","key":"6705_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/hr.2016.2","volume":"39","author":"Y Takeshige","year":"2016","unstructured":"Takeshige Y, Fujisawa Y, Rahman A et al (2016) A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens Res 39(6):415\u2013422. https:\/\/doi.org\/10.1038\/hr.2016.2","journal-title":"Hypertens Res"},{"key":"6705_CR22","doi-asserted-by":"publisher","unstructured":"Kravtsova O, Bohovyk R, Levchenko V et al (2022) SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats. Am J Physiol Renal Physiol 322(6):F692\u2013F707. https:\/\/doi.org\/10.1152\/AJPRENAL.00053.2022","DOI":"10.1152\/AJPRENAL.00053.2022"},{"key":"6705_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/FENDO.2018.00421\/BIBTEX","volume":"9","author":"N Wan","year":"2018","unstructured":"Wan N, Rahman A, Hitomi H, Nishiyama A (2018) The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol (Lausanne) 9:421. https:\/\/doi.org\/10.3389\/FENDO.2018.00421","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"6705_CR24","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/s41440-019-0326-3","volume":"42","author":"S Kim","year":"2019","unstructured":"Kim S, Jo CH, Kim GH (2019) Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. Hypertens Res 42(12):1905\u20131915. https:\/\/doi.org\/10.1038\/s41440-019-0326-3","journal-title":"Hypertens Res"},{"issue":"24","key":"6705_CR25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMOA1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMOA1811744","journal-title":"N Engl J Med"},{"issue":"11","key":"6705_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/AJE\/KWT066","volume":"177","author":"IJ Brown","year":"2013","unstructured":"Brown IJ, Dyer AR, Chan Q et al (2013) Estimating 24-hour urinary sodium excretion from casual urinary sodium concentrations in Western populations: the INTERSALT study. Am J Epidemiol 177(11):1180\u20131192. https:\/\/doi.org\/10.1093\/AJE\/KWT066","journal-title":"Am J Epidemiol"},{"issue":"7","key":"6705_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41440-021-00632-2","volume":"44","author":"S Kodama","year":"2021","unstructured":"Kodama S, Horikawa C, Fujihara K et al (2021) Meta-analytic research of the dose-response relationship between salt intake and risk of heart failure. Hypertens Res 44(7):885\u2013887. https:\/\/doi.org\/10.1038\/s41440-021-00632-2","journal-title":"Hypertens Res"},{"key":"6705_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/J.PCAD.2024.01.004","volume":"82","author":"E Colin-Ramirez","year":"2024","unstructured":"Colin-Ramirez E, Arcand J, Saldarriaga C, Ezekowitz JA (2024) The current state of evidence for sodium and fluid restriction in heart failure. Prog Cardiovasc Dis 82:43\u201354. https:\/\/doi.org\/10.1016\/J.PCAD.2024.01.004","journal-title":"Prog Cardiovasc Dis"},{"issue":"10333","key":"6705_CR29","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0140-6736(22)00369-5","volume":"399","author":"JA Ezekowitz","year":"2022","unstructured":"Ezekowitz JA, Colin-Ramirez E, Ross H et al (2022) Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet 399(10333):1391\u20131400. https:\/\/doi.org\/10.1016\/S0140-6736(22)00369-5","journal-title":"Lancet"},{"issue":"4\u20135","key":"6705_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000173402","volume":"14","author":"JP Briggs","year":"1991","unstructured":"Briggs JP, Lorenz JN, Weihprecht H, Schnermann J (1991) Macula densa control of renin secretion. Ren Physiol Biochem 14(4\u20135):164\u2013174. https:\/\/doi.org\/10.1159\/000173402","journal-title":"Ren Physiol Biochem"},{"issue":"11","key":"6705_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/AJH\/3.11.863","volume":"3","author":"GA Sagnella","year":"1990","unstructured":"Sagnella GA, Markandu ND, Buckley MG, Miller MA, Singer DRJ, MacGregor GA (1990) Plasma atrial natriuretic peptide, aldosterone, and plasma renin activity responses to gradual changes in dietary sodium intake. Am J Hypertens 3(11):863\u2013865. https:\/\/doi.org\/10.1093\/AJH\/3.11.863","journal-title":"Am J Hypertens"},{"issue":"1","key":"6705_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","volume":"14","author":"J Hartupee","year":"2016","unstructured":"Hartupee J, Mann DL (2016) Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol 14(1):30\u201338. https:\/\/doi.org\/10.1038\/nrcardio.2016.163","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"6705_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","volume":"20","author":"M Packer","year":"1992","unstructured":"Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20(1):248\u2013254. https:\/\/doi.org\/10.1016\/0735-1097(92)90167-L","journal-title":"J Am Coll Cardiol"},{"key":"6705_CR34","doi-asserted-by":"publisher","first-page":"e09","DOI":"10.15420\/CFR.2022.23","volume":"9","author":"V Castiglione","year":"2023","unstructured":"Castiglione V, Gentile F, Ghionzoli N et al (2023) Pathophysiological rationale and clinical evidence for neurohormonal modulation in heart failure with preserved ejection fraction. Card Fail Rev 9:e09. https:\/\/doi.org\/10.15420\/CFR.2022.23","journal-title":"Card Fail Rev"},{"issue":"1","key":"6705_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/S10741-022-10228-8\/FIGURES\/1","volume":"28","author":"A Aimo","year":"2023","unstructured":"Aimo A, Senni M, Barison A et al (2023) Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart Fail Rev 28(1):179\u2013191. https:\/\/doi.org\/10.1007\/S10741-022-10228-8","journal-title":"Heart Fail Rev"},{"issue":"5","key":"6705_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531\/ASSET\/05E36B2A-AF46-41FA-9A05-33306038DB50\/ASSETS\/GRAPHIC\/15MM1.JPEG","volume":"55","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Corros C, Pimenta E et al (2010) Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 55(5):1137\u20131142. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.141531","journal-title":"Hypertension"},{"key":"6705_CR37","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/CFR.2023.05","volume":"9","author":"B Shahim","year":"2023","unstructured":"Shahim B, Kapelios CJ, Savarese G, Lund LH (2023) Global public health burden of heart failure: an updated review. Card Fail Rev 9:e11. https:\/\/doi.org\/10.15420\/CFR.2023.05","journal-title":"Card Fail Rev"},{"issue":"4","key":"6705_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346\/ASSET\/445AF5D9-0E3F-4BB0-9978-9AA69A06EBEE\/ASSETS\/GRAPHIC\/CIRCULATIONAHA.123.064346.FIG02.JPG","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer M, Wilcox CS, Testani JM (2023) Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes. Circulation 148(4):354\u2013372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064346","journal-title":"Circulation"},{"issue":"11","key":"6705_CR39","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","volume":"146","author":"CG Santos-Gallego","year":"2022","unstructured":"Santos-Gallego CG, Mayr M, Badimon J (2022) SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism. Circulation 146(11):819\u2013821. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060805","journal-title":"Circulation"},{"issue":"11","key":"6705_CR40","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/DC15-2688","volume":"39","author":"G Daniele","year":"2016","unstructured":"Daniele G, Xiong J, Solis-Herrera C et al (2016) Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 39(11):2036\u20132041. https:\/\/doi.org\/10.2337\/DC15-2688","journal-title":"Diabetes Care"},{"issue":"2","key":"6705_CR41","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/S13300-018-0385-5\/FIGURES\/2","volume":"9","author":"A Yasui","year":"2018","unstructured":"Yasui A, Lee G, Hirase T et al (2018) Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes. Diabetes Ther 9(2):863\u2013871. https:\/\/doi.org\/10.1007\/S13300-018-0385-5","journal-title":"Diabetes Ther"},{"issue":"6","key":"6705_CR42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2337\/dc16-2724","volume":"40","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E, Baldi S, Frascerra S et al (2017) Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 40(6):771\u2013776. https:\/\/doi.org\/10.2337\/dc16-2724","journal-title":"Diabetes Care"},{"issue":"16","key":"6705_CR43","doi-asserted-by":"publisher","first-page":"e016270","DOI":"10.1161\/JAHA.120.016270\/ASSET\/D406098D-E814-4684-940C-B62C38557078\/ASSETS\/GRAPHIC\/JAH35240-FIG-0001.PNG","volume":"9","author":"M Packer","year":"2020","unstructured":"Packer M (2020) Molecular, cellular, and clinical evidence that sodium-glucose cotransporter 2 inhibitors act as neurohormonal antagonists when used for the treatment of chronic heart failure. J Am Heart Assoc 9(16):e016270. https:\/\/doi.org\/10.1161\/JAHA.120.016270","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"6705_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-020-01127-Z\/TABLES\/4","volume":"19","author":"W Shimizu","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y et al (2020) Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 19(1):1\u201312. https:\/\/doi.org\/10.1186\/S12933-020-01127-Z","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"6705_CR45","doi-asserted-by":"publisher","first-page":"e022637","DOI":"10.1161\/JAHA.121.022637","volume":"10","author":"T Hamaoka","year":"2021","unstructured":"Hamaoka T, Murai H, Hirai T et al (2021) Different responses of muscle sympathetic nerve activity to dapagliflozin between patients with type 2 diabetes with and without heart failure. J Am Heart Assoc 10(22):e022637. https:\/\/doi.org\/10.1161\/JAHA.121.022637","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"6705_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/IJMS20030629","volume":"20","author":"TM Ansary","year":"2019","unstructured":"Ansary TM, Nakano D, Nishiyama A (2019) Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci 20(3):629. https:\/\/doi.org\/10.3390\/IJMS20030629","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6705_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/S12933-019-0852-Y\/FIGURES\/4","volume":"18","author":"A Schork","year":"2019","unstructured":"Schork A, Saynisch J, Vosseler A et al (2019) Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol 18(1):46. https:\/\/doi.org\/10.1186\/S12933-019-0852-Y","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"6705_CR48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1507\/ENDOCRJ.EJ18-0022","volume":"65","author":"T Nomiyama","year":"2018","unstructured":"Nomiyama T, Shimono D, Horikawa T et al (2018) Efficacy and safety of sodium\u2013glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). Endocr J 65(8):859\u2013867. https:\/\/doi.org\/10.1507\/ENDOCRJ.EJ18-0022","journal-title":"Endocr J"},{"issue":"Supplement_1","key":"6705_CR49","doi-asserted-by":"publisher","first-page":"1196-P","DOI":"10.2337\/DB18-1196-P","volume":"67","author":"I Mori","year":"2018","unstructured":"Mori I, Ishizuka T (2018) Effects of SGLT2 inhibitors on renin-aldosterone system for one month and six months in type 2 diabetes. Diabetes 67(Supplement_1):1196-P. https:\/\/doi.org\/10.2337\/DB18-1196-P","journal-title":"Diabetes"},{"issue":"7","key":"6705_CR50","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/JIM-2017-000445","volume":"65","author":"T Yoshimoto","year":"2017","unstructured":"Yoshimoto T, Furuki T, Kobori H et al (2017) Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med 65(7):1057\u20131061. https:\/\/doi.org\/10.1136\/JIM-2017-000445","journal-title":"J Investig Med"},{"issue":"12","key":"6705_CR51","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cardfail.2021.07.003","volume":"27","author":"P Bjornstad","year":"2021","unstructured":"Bjornstad P, Greasley PJ, Wheeler DC et al (2021) The potential roles of osmotic and nonosmotic sodium handling in mediating the effects of sodium-glucose cotransporter 2 inhibitors on heart failure. J Card Fail 27(12):1447\u20131455. https:\/\/doi.org\/10.1016\/j.cardfail.2021.07.003","journal-title":"J Card Fail"},{"issue":"1","key":"6705_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01385-5","volume":"20","author":"A Natali","year":"2021","unstructured":"Natali A, Nesti L, Tric\u00f2 D, Ferrannini E (2021) Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol 20(1):1\u201316. https:\/\/doi.org\/10.1186\/s12933-021-01385-5","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"6705_CR53","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/0004563217728964","volume":"55","author":"TP Griffin","year":"2018","unstructured":"Griffin TP, Wall D, Browne GA, Dennedy MC, O\u2019Shea PM (2018) Associations between glycaemic control and activation of the renin-angiotensin-aldosterone system in participants with type 2 diabetes mellitus and hypertension. Ann Clin Biochem 55(3):373\u2013384. https:\/\/doi.org\/10.1177\/0004563217728964","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"6705_CR54","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0895-7061(98)00265-9","volume":"12","author":"DA Price","year":"1999","unstructured":"Price DA, De\u2019Oliveira JMF, Fisher NDL, Williams GH, Hollenberg NK (1999) The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens 12(4):348\u2013355. https:\/\/doi.org\/10.1016\/S0895-7061(98)00265-9","journal-title":"Am J Hypertens"},{"issue":"3","key":"6705_CR55","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/ki.1997.394","volume":"52","author":"JM De\u2019Oliveira","year":"1997","unstructured":"De\u2019Oliveira JM, Price DA, Fisher NDL et al (1997) Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 52(3):771\u2013777. https:\/\/doi.org\/10.1038\/ki.1997.394","journal-title":"Kidney Int"},{"issue":"5","key":"6705_CR56","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1681\/ASN.V85749","volume":"8","author":"JA Miller","year":"1997","unstructured":"Miller JA (1997) Renal responses to sodium restriction in patients with early diabetes mellitus. J Am Soc Nephrol 8(5):749\u2013755. https:\/\/doi.org\/10.1681\/ASN.V85749","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"6705_CR57","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMOA1611925\/SUPPL_FILE\/NEJMOA1611925_DISCLOSURES.PDF","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMOA1611925\/SUPPL_FILE\/NEJMOA1611925","journal-title":"N Engl J Med"},{"issue":"6","key":"6705_CR58","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1161\/01.HYP.25.6.1339\/ASSET\/B6A71197-17EF-4813-BD0F-E78BBC945257\/ASSETS\/GRAPHIC\/HY0650712004.JPEG","volume":"25","author":"MR Weir","year":"1995","unstructured":"Weir MR, Dengel DR, Behrens MT, Goldberg AP (1995) Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 25(6):1339\u20131344. https:\/\/doi.org\/10.1161\/01.HYP.25.6.1339","journal-title":"Hypertension"},{"issue":"10","key":"6705_CR59","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/AJH\/HPT294","volume":"27","author":"A Smyth","year":"2014","unstructured":"Smyth A, O\u2019Donnell MJ, Yusuf S et al (2014) Sodium intake and renal outcomes: a systematic review. Am J Hypertens 27(10):1277\u20131284. https:\/\/doi.org\/10.1093\/AJH\/HPT294","journal-title":"Am J Hypertens"},{"issue":"3","key":"6705_CR60","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/NDT\/GFAA107","volume":"36","author":"M Kang","year":"2021","unstructured":"Kang M, Kang E, Ryu H et al (2021) Measured sodium excretion is associated with CKD progression: results from the KNOW-CKD study. Nephrol Dial Transplant 36(3):512\u2013519. https:\/\/doi.org\/10.1093\/NDT\/GFAA107","journal-title":"Nephrol Dial Transplant"},{"key":"6705_CR61","volume-title":"WHO Global report on sodium intake reduction","author":"World Health Organization","year":"2023","unstructured":"World Health Organization (2023) WHO Global report on sodium intake reduction. World Health Organization, Geneva"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06705-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06705-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06705-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:39:07Z","timestamp":1773329947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06705-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":61,"alternative-id":["6705"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06705-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors thank all participants and investigators of CREDENCE. The CREDENCE trial was sponsored by Janssen Research and Development, LLC. Canagliflozin was developed by Janssen Research & Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation. The graphical abstract was created with BioRender.com.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"Clinical data from the CREDENCE trial are available in the public domain via the Yale University Open Data Access Project (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The CREDENCE trial was funded by Janssen Research and Development, LLC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MC has received honoraria for participation at scientific meetings from Novo Nordisk. DT has received honoraria for participation at scientific meetings and advisory boards from Eli Lilly, Amarin, AstraZeneca and Novo Nordisk. AN has received honoraria for participation in scientific meetings and advisory boards from Eli Lilly and Boehringer Ingelheim. EF holds a research grant from Janssen, has held research grants from Boehringer Ingelheim and has received consultancy or speaker fees from Sanofi, Boehringer Ingelheim, ORAMED and Lilly & Co. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"MC, AN and EF contributed to the study conceptualisation, investigation, methodology, supervision and validation, writing the original draft and reviewing and editing the manuscript. SB and TS conducted the laboratory assays. DT, AG, LS, LN, SB, TS and VC contributed to the investigation, and reviewed and edited the manuscript. All authors read and approved the manuscript. MC and EF are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}